Association of CYP1A1 and GSTM1 Polymorphisms With Oral Cancer Susceptibility: A Meta-Analysis
Overview
Authors
Affiliations
Our meta-analysis was aimed to evaluate the association of CYP1A1 and glutathione-S-transferase M1 (GSTM1) polymorphisms with oral cancer susceptibility.The related articles were searched in PubMed, Embase, and CNKI databases. Fifty eligible studies were included in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the relationship of CYP1A1 (rs4646903 and rs1048943) and GSTM1 polymorphisms with oral cancer risk. A random-effects model or fixed-effects model was employed depending on the heterogeneity.In overall analysis, CYP1A1 rs4646903 polymorphism was associated with the risk of oral cancer (CC vs TT: OR 1.65, 95% CI 1.33-2.05; CC vs TC+TT: OR 1.77, 95% CI 1.48-2.11; C vs T: OR 1.17, 95% CI 1.07-1.28), whereas rs1048943 showed no obvious association with oral cancer susceptibility. Moreover, subgroup analysis by ethnicity demonstrated that rs4646903 and rs1048943 both related with increased risk of oral cancer in Asians. Moreover, the analysis based on source of control suggested that rs4646903 could increase the risk for oral cancer in both population- and hospital-based populations, whereas no remarkable relationship of rs1048943 with oral cancer susceptibility was observed. For GSTM1 gene, null genotype appeared to be a risk factor for oral cancer (null vs present: OR 1.23, 95% CI 1.12-1.34), which was also proved in the subgroup analysis.The results demonstrated that CYP1A1 rs4646903 and null genotype of GSTM1 polymorphisms might serve as risk factors for oral cancer.
Genetic and Molecular Differences in Head and Neck Cancer Based on Smoking History.
Jiang R, Gao M, Chen M, Weatherspoon D, Watts T, Osazuwa-Peters N JAMA Otolaryngol Head Neck Surg. 2025; .
PMID: 40048195 PMC: 11886874. DOI: 10.1001/jamaoto.2024.5409.
Interaction between CYP1A1 gene polymorphism and environment factors on risk of endometrial cancer.
Xu J, Tan C Environ Health Prev Med. 2024; 29:54.
PMID: 39384367 PMC: 11473388. DOI: 10.1265/ehpm.24-00007.
Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X Acta Pharm Sin B. 2020; 10(1):91-104.
PMID: 31998606 PMC: 6984740. DOI: 10.1016/j.apsb.2019.11.016.
Saravani S, Miri-Moghaddam M, Bazi A, Miri-Moghaddam E Asian Pac J Cancer Prev. 2019; 20(6):1921-1926.
PMID: 31244319 PMC: 7021601. DOI: 10.31557/APJCP.2019.20.6.1921.
Lin C, Chu C, Su S PLoS One. 2016; 11(4):e0152891.
PMID: 27045371 PMC: 4821560. DOI: 10.1371/journal.pone.0152891.